The pathophysiology of NAFL and NASH is complex and numerous intermediaries are
involved. Each year brings new and exciting developments as pieces of the …

Background Non-alcoholic fatty liver disease (NAFLD) is a clinicopathologic entity that
requires a liver biopsy assessment to diagnose the progressive form of NAFLD called non …

This guidance provides a data-supported approach to risk stratification, diagnosis, and
management of patients with cirrhosis and portal hypertension (PH). A guidance document …

Background Glucagon‐like peptide‐1 receptor agonists may be a treatment option in
patients with non‐alcoholic fatty liver disease (NAFLD). Aims To investigate the effects of …

Liver fibrosis should be assessed in all individuals with chronic liver disease as it predicts
the risk of future liver-related morbidity and thus need for treatment, monitoring and …

With the increasing number of individuals with diabetes and obesity, nonalcoholic fatty liver
disease (NAFLD) is becoming increasingly prevalent, affecting one-quarter of adults …

The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing rapidly worldwide
as the obese and diabetic populations increase, and it has been estimated to be 20–30% in …

Chronic liver diseases often result in the development of liver fibrosis and ultimately,
cirrhosis. Treatment strategies and prognosis differ greatly depending on the severity of liver …

In patients with compensated advanced chronic liver disease (cACLD), the presence of
clinically significant portal hypertension (CSPH) and varices needing treatment (VNT) bears …

Non-alcoholic fatty liver disease (NAFLD) represents one of the most common causes of
chronic liver disease, and its prevalence is rising worldwide. The occurrence of non …